A healthcare investor led a $100m Series D round in Neuron23.

A healthcare investor led a $100m Series D round in Neuron23, a clinical-stage biotechnology company, with participation from Westlake Village BioPartners, SoftBank Vision Fund 2, Redmile Group, Blue Owl, Kleiner Perkins, HBM Healthcare Investments (Cayman), and Acorn Bioventures. "The Series D financing represents further endorsement of Neuron23’s industry-leading approach, which leverages state-of-the-art precision medicine and patient identification to deliver NEU-411 to people with Parkinson’s disease who are most likely to benefit from LRRK2 inhibition, increasing probability of success in the clinic and bringing the right therapy to the right patients," Nancy Stagliano, Neuron23 CEO.